2026 Summer Intern PhD Student Drug Delivery at Bristol-Myers Squibb

New Brunswick, New Jersey, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

Currently enrolled in an accredited university PhD program
Demonstrated innovative problem-solving ability
Ability to work in a fast-paced team environment
Self-motivated and highly self-driven
Prior drug product development research experience is a plus

Responsibilities

Conducting feasibility experiments with formulation technologies (e.g., immediate release to long-acting injectable formulations including API suspension, polymer-based, and lipid-based systems)
Formulation development for various model compounds
Chemical and physical characterization of formulations
Development and refinement of in vitro release assays to characterize products
Analytical methods to evaluate key quality attributes
Building in vitro-in vivo correlations (IVIVC) for subcutaneous (SC) and intramuscular (IM) injections using existing in vitro, in vivo, and in-silico methodologies (e.g., GastroPlus, physiologically based pharmacokinetic (PBPK) models, and pharmacokinetic models)

Skills

Drug Formulation

Long-Acting Injectables

API Suspension

Polymer-based Systems

Lipid-based Systems

In Vitro Release Assays

Analytical Methods

GastroPlus

IVIVC

Subcutaneous Injections

Intramuscular Injections

Preclinical Studies

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free